NCT05429385View on ClinicalTrials.gov

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 9, 2020

Primary Completion Date

September 6, 2021

Study Completion Date

September 18, 2021

Conditions

COVID-19

Interventions

DRUG

HLX70

Single-dose, intravenous infusion

DRUG

Placebo

Single-dose, intravenous infusion

Sponsors

Collaborators (1)

Hengenix Biotech Inc

All Listed Sponsors

collaborator

Hengenix Biotech Inc

INDUSTRY

collaborator

Sanyou Biopharmaceuticals(Shanghai)Co., Ltd

UNKNOWN

collaborator

Shanghai ZJ Bio-Tech Co., Ltd

UNKNOWN

lead

Shanghai Henlius Biotech

INDUSTRY